Genomics firm GeneDx beats Q3 revenue estimates, raises outlook

GeneDx Holdings

28/10/2025 10:41

Overview

GeneDx Q3 2025 rev grows 52% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

Company raises full-year revenue guidance to $425-$428 mln

Outlook

GeneDx raises full-year 2025 revenue guidance to $425-$428 mln

Company expects 53%-55% growth in exome and genome revenue for 2025

GeneDx anticipates 70%-71% adjusted gross margin for full year 2025

Result Drivers

EXOME AND GENOME GROWTH - Exome and genome test revenue grew 65% yr/yr, driven by a 33% increase in test volumes

FDA DESIGNATION - FDA Breakthrough Device Designation for ExomeDx™ and GenomeDx™ highlights innovative leadership

NEWBORN SCREENING LEADERSHIP - Co leads in genomic newborn screening as sole commercial provider for new programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$116.70 mln
$104.10 mln (7 Analysts)
Q3 Adjusted EPS
Beat
$0.49
$0.39 (5 Analysts)
Q3 Adjusted Net Income
$14.70 mln
Q3 Net Income
-$7.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for GeneDx Holdings Corp is $125.00, about 4.5% below its October 27 closing price of $130.66

The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 60 three months ago

Press Release: ID:nBw7zGs5qa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)